Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies

The Gleason grading system is a powerful tool to prognosticate and aid in the treatment of men with prostate cancer. The needle biopsy Gleason score correlates with virtually all other pathological variables, including tumour volume and margin status in radical prostatectomy specimens, serum prostate‐specific antigen levels and many molecular markers. The Gleason score assigned to the tumour at radical prostatectomy is the most powerful predictor of progression after radical prostatectomy. However, there are significant deficiencies in the practice of this grading system. Not only are there problems among practising pathologists but also a relative lack of interobserver reproducibility among experts.

[1]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[2]  J. Segura,et al.  Representación del "score" Gleason en la biopsia prostática del "score" Gleason definitivo de la prostatectomía radical , 2004 .

[3]  Joseph A. Smith,et al.  Predicting the presence and side of extracapsular extension: A nomogram for staging prostate cancer , 2004 .

[4]  M. Rubin,et al.  Should a Gleason Score Be Assigned to a Minute Focus of Carcinoma on Prostate Biopsy? , 2000, The American journal of surgical pathology.

[5]  R. Motzer,et al.  Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Pan,et al.  The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. , 2000, The American journal of surgical pathology.

[7]  M. Gramatzki,et al.  IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial , 2001, British Journal of Cancer.

[8]  M. Fishman,et al.  Cell-based immune therapy for metastatic renal cancer , 2003, Expert review of anticancer therapy.

[9]  F. Ognibene,et al.  Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. , 1988, Chest.

[10]  J. Bishoff,et al.  Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. , 2003, Urology.

[11]  S. Négrier.  Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Zimmerman,et al.  Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. , 2001, The Journal of urology.

[13]  H. Heinzer,et al.  Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. , 2003, Folia biologica.

[14]  The Gleason Grading System: An Overview , 1999 .

[15]  G. Jakse,et al.  Therapy of local recurrence of renal cell carcinoma. , 2002, Oncology reports.

[16]  G. Wilding,et al.  Angiogenesis inhibitors in genitourinary cancers. , 2003, Critical reviews in oncology/hematology.

[17]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[18]  P. Albers,et al.  Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. , 2003, Human gene therapy.

[19]  M. Kattan,et al.  Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. , 2004, The Journal of urology.

[20]  S. Campbell,et al.  Metastatic renal cell carcinoma , 2003, Current treatment options in oncology.

[21]  A. D'Amico,et al.  Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. , 1997, Urology.

[22]  L. Schwartz,et al.  Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials , 2003, Cancer.

[23]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[24]  J. Hinshaw,et al.  Image-guided ablation of renal cell carcinoma. , 2004, Magnetic resonance imaging clinics of North America.

[25]  B. Wowra,et al.  [Ambulatory radiosurgery in cerebral metastatic renal cell carcinoma. 5-year outcome in 58 patients]. , 2002, Der Urologe. Ausg. A.

[26]  A. Evans,et al.  Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. , 2004, The Canadian journal of urology.

[27]  J. Posner,et al.  Management of brain metastases. , 1992, Revue neurologique.

[28]  R. Amato.  Thalidomide therapy for renal cell carcinoma. , 2003, Critical reviews in oncology/hematology.

[29]  J. Chin,et al.  New technologies for ablation of small renal tumors: current status. , 2002, The Canadian journal of urology.

[30]  S. Fosså,et al.  Interferon in metastatic renal cell carcinoma. , 2000, Seminars in oncology.

[31]  D. Mahvi,et al.  Cryoablation and liver resection for noncolorectal liver metastases. , 2002, American journal of surgery.

[32]  P. E. Bernatz,et al.  The treatment of renal cell carcinoma with solitary metastasis. , 1978, The Journal of urology.

[33]  R. Childs,et al.  Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement. , 2003, The Urologic clinics of North America.

[34]  A W Partin,et al.  Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. , 2000, Urology.

[35]  M. Kahn,et al.  A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma , 1997, Cancer.

[36]  R. Oyasu,et al.  The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. , 1984, The Journal of urology.

[37]  P. Humphrey,et al.  Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens , 2005, Scandinavian journal of urology and nephrology. Supplementum.

[38]  S. Culine,et al.  Prognostic factors for survival in patients with brain metastases from renal cell carcinoma , 1998, Cancer.

[39]  R. Amato.  Chemotherapy for renal cell carcinoma. , 2000, Seminars in oncology.

[40]  H. Dienemann,et al.  Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. , 2002, The Annals of thoracic surgery.

[41]  P. Dayton,et al.  Renal cell carcinoma and osseous metastases. Case report and literature review. , 1989, Journal of the American Podiatric Medical Association (Print).

[42]  Y. Collan,et al.  Prognostic factors in prostate cancer , 2006, Diagnostic pathology.

[43]  J. Yang.  Bevacizumab for Patients with Metastatic Renal Cancer , 2004, Clinical Cancer Research.

[44]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  K. Lillemoe,et al.  Renal cell carcinoma metastatic to the pancreas: Results of surgical management , 2000, Journal of Gastrointestinal Surgery.

[46]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[47]  M. Maor,et al.  Palliative radiotherapy for brain metastases in renal carcinoma , 1988, Cancer.

[48]  M. Terris,et al.  The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy , 2003, Cancer.

[49]  M. Wichmann,et al.  Long-term results after pulmonary resection of renal cell carcinoma metastases. , 2002, The Annals of thoracic surgery.

[50]  M. L. Cintra,et al.  Histologic grading of prostatic adenocarcinoma: Intraobserver reproducibility of the Mostofi, Gleason and Böcking grading systems , 2007, International Urology and Nephrology.

[51]  Sten Nilsson,et al.  Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens , 2005, Scandinavian journal of urology and nephrology. Supplementum.

[52]  Hartwig Huland,et al.  Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. , 2003, The Journal of urology.

[53]  M. Mazumdar,et al.  Predicting survival of patients with metastatic renal cell carcinoma , 2004, Der Urologe.

[54]  T. Tsuzuki,et al.  The Prognostic Significance of Tertiary Gleason Pattern 5 in Radical Prostatectomy Specimens , 2004, The American journal of surgical pathology.

[55]  T. Yoshino,et al.  [Bevacizumab (Avastin)]. , 2007, Gan to kagaku ryoho. Cancer & chemotherapy.

[56]  H. Heinzer,et al.  Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). , 1999, Anticancer research.

[57]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[58]  R. Cohen,et al.  Gleason Grading of Prostate Cancer: A Contemporary Approach , 2004 .

[59]  J. Epstein,et al.  Should each core with prostate cancer be assigned a separate gleason score? , 2003, Human pathology.

[60]  M. Wirth,et al.  Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. , 2002, The Journal of urology.

[61]  Alan W Partin,et al.  Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? , 2002, The Journal of urology.

[62]  L. Schwartz,et al.  Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Pierre I Karakiewicz,et al.  Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. , 2004, The Journal of urology.

[64]  Juni Palmgren,et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.

[65]  D. Gervais,et al.  Percutaneous Radiofrequency Ablation of Nodal Metastases , 2002, CardioVascular and Interventional Radiology.

[66]  O. Ogawa,et al.  Low incidence of ipsilateral adrenal involvement and recurrences in patients with renal cell carcinoma undergoing radical nephrectomy: a retrospective analysis of 393 patients. , 2003, Urology.

[67]  K. Grankvist,et al.  Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. , 2000, The Journal of urology.

[68]  Ximing J. Yang,et al.  Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. , 2003, The Journal of urology.

[69]  A. El‐Naggar,et al.  Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. , 2001, The American journal of pathology.

[70]  G. Martiny-Baron,et al.  Effects of PTK 787 / ZK 222584 , a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , on Primary Tumor , Metastasis , Vessel Density , and Blood Flow in a Murine Renal Cell Carcinoma Model 1 , 2000 .

[71]  A. Moinzadeh,et al.  Histopathologic confirmation of complete cancer-cell kill in excised specimens after renal cryotherapy. , 2004, Urology.

[72]  C. Busch,et al.  Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. , 1994, Scandinavian journal of urology and nephrology. Supplementum.

[73]  N. Smith,et al.  Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. , 1997, The Journal of urology.

[74]  S. Loening,et al.  Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. F. Calvin H. L. Law MPH,et al.  Pancreatic Resection for Metastatic Renal Cell Carcinoma: Presentation, Treatment, and Outcome , 2003, Annals of Surgical Oncology.

[76]  S. Piantadosi,et al.  Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. , 1997, The American journal of surgical pathology.

[77]  R. Badalament,et al.  Surgical treatment of brain metastases from renal cell carcinoma. , 1990, Urology.

[78]  M. Dimopoulos,et al.  Thalidomide in cancer medicine. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  A. Buzaid,et al.  Dendritic cell–tumor cell hybrid vaccination for metastatic cancer , 2004, Cancer Immunology, Immunotherapy.

[80]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  S. Mills,et al.  Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens , 1986, Cancer.

[82]  D. Petrylak,et al.  Cytotoxic chemotherapy for advanced renal cell carcinoma. , 1993, The Urologic clinics of North America.

[83]  K. McVary,et al.  Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate , 1995, Cancer.

[84]  M. Banerjee,et al.  Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. , 2000, Urology.

[85]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[86]  S. Culine,et al.  A Phase II study of irinotecan in patients with advanced renal cell carcinoma , 2003, Cancer.

[87]  [Evidence of the radical prostatectomy Gleason score in the biopsy Gleason score]. , 2004, Actas urologicas espanolas.

[88]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[89]  L. Damico,et al.  A Phase II Study of Thalidomide in Advanced Metastatic Renal Cell Carcinoma , 2002, Investigational New Drugs.

[90]  M. Wyczółkowski,et al.  Spontaneous Regression of Hepatic Metastases after Nephrectomy and Metastasectomy of Renal Cell Carcinoma , 2001, Urologia Internationalis.

[91]  T. de Baère,et al.  Adverse events during radiofrequency treatment of 582 hepatic tumors. , 2003, AJR. American journal of roentgenology.

[92]  R. Motzer,et al.  Phase II trial of thalidomide for patients with advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[94]  J. Harrelson,et al.  Treatment of Osseous Metastases in Patients With Renal Cell Carcinoma , 2003, Clinical orthopaedics and related research.

[95]  D. Petrylak,et al.  Chemotherapy for advanced renal-cell carcinoma: 1983-1993. , 1995, Seminars in oncology.

[96]  A. Partin,et al.  Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.

[97]  D. Ruiter,et al.  Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney , 1986, International journal of cancer.

[98]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[99]  A. Schned,et al.  Acquired renal cystic disease and renal cell carcinoma in an allograft kidney. , 1995, The Journal of urology.

[100]  A. Partin,et al.  Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage , 1990, Cancer.

[101]  A. Weaver,et al.  Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: An institutional review , 1994, Annals of Surgical Oncology.

[102]  A. Hofstetter,et al.  Large de novo renal cell carcinoma in a 10-year-old transplanted kidney: successful organ-preserving therapy. , 2000, Transplantation.

[103]  D. Bostwick,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. , 2001, Human pathology.

[104]  P. Russo,et al.  Surgical resection of brain metastases from renal cell carcinoma in 50 patients. , 1996, Urology.

[105]  A. Tubaro.  Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. , 2000 .

[106]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[107]  J. Douillard,et al.  [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]. , 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[108]  H. Joensuu,et al.  Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  R. Figlin,et al.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  M. Fishman,et al.  Novel therapies for renal cell carcinoma – an update , 2003, Expert opinion on investigational drugs.

[111]  R. Paridaens,et al.  Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. , 1994, European journal of cancer.

[112]  A. Muacevic,et al.  Repeated gamma knife surgery for multiple brain metastases from renal cell carcinoma. , 2002, Journal of neurosurgery.

[113]  A. Novick,et al.  The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. , 1994, The Journal of urology.

[114]  M. Ratain,et al.  Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[116]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  B. Kremer,et al.  Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[118]  C. Falk,et al.  Renal cell carcinoma‐infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes , 2003, International journal of cancer.

[119]  S. Rajkumar,et al.  Management of thalidomide toxicity. , 2003, The journal of supportive oncology.

[120]  R. Figlin,et al.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. , 2003, The Urologic clinics of North America.

[121]  J. Cheville,et al.  A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. , 2004, The Journal of urology.

[122]  Ş. Özdamar,et al.  Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas , 2006, International Urology and Nephrology.

[123]  G. Reynés,et al.  Toxic Epidermal Necrolysis Associated with Interleukin-2 , 2002, The Annals of pharmacotherapy.

[124]  N. Rioux-Leclercq,et al.  Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. , 2002, Urology.

[125]  R. Figlin,et al.  A Pilot Trial of Tumor Lysate-Loaded Dendritic Cells for the Treatment of Metastatic Renal Cell Carcinoma , 2003, Journal of immunotherapy.

[126]  D. Lubeck,et al.  Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. , 2000, The Journal of urology.

[127]  J. Epstein,et al.  Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. , 2000, The American journal of surgical pathology.

[128]  J. Douillard,et al.  A Phase II Study with 5-Fluorouracil, Folinic Acid and Oxaliplatin (FOLFOX-4 Regimen) in Patients with Metastatic Renal Cell Carcinoma , 2002, Oncology.

[129]  M. Stöckle,et al.  Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. , 2004, The Journal of urology.

[130]  W. Lehmacher,et al.  Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial , 2004, The Lancet.

[131]  岸本 正雄.  SPONTANEOUS regression. , 1967, Cancer bulletin.

[132]  M. Wichmann,et al.  [Surgical treatment of pulmonary metastases from renal cancer]. , 2003, Der Urologe. Ausg. A.

[133]  Lars Egevad,et al.  Current practice of Gleason grading among genitourinary pathologists. , 2005, Human pathology.

[134]  D. Nicol,et al.  Renal cell carcinoma may adapt to and overcome anti‐angiogenic intervention with thalidomide , 2002, BJU international.

[135]  M. Dimopoulos,et al.  Adverse effects of thalidomide administration in patients with neoplastic diseases. , 2004, The American journal of medicine.

[136]  Martin R. Schneider,et al.  PTK 787 / ZK 222584 , a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration , 2000 .

[137]  M. Rubin,et al.  Prostate Needle Biopsy Reporting: How Are the Surgical Members of the Society of Urologic Oncology Using Pathology Reports to Guide Treatment of Prostate Cancer Patients? , 2004, The American journal of surgical pathology.

[138]  B. Rini,et al.  Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  S. Steinberg,et al.  A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma , 2004, Journal of immunotherapy.

[140]  N. Bander,et al.  Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  L. Hertle,et al.  Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). , 1999, Anticancer research.

[142]  T. Tammela,et al.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[144]  R. Childs,et al.  Allogeneic stem cell transplantation for renal cell carcinoma , 2001, Current opinion in urology.

[145]  G Vallancien,et al.  Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute. , 2003, The Journal of urology.

[146]  J. Epstein,et al.  The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers. , 2003, Pathology.

[147]  R. Motzer,et al.  Novel investigative approaches for advanced renal cell carcinoma. , 2000, Seminars in oncology.

[148]  H. Dürr,et al.  Surgical treatment of osseous metastases in patients with renal cell carcinoma. , 1999, Clinical orthopaedics and related research.

[149]  G. Dini,et al.  Hematopoetic stem cell transplantation for solid tumors in Europe. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[150]  R. Figlin,et al.  Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. , 2003, The Journal of urology.

[151]  T. Wheeler,et al.  Heterogeneity of prostate cancer in radical prostatectomy specimens. , 1994, Urology.

[152]  S. Nakada,et al.  Renal cryotherapy: 2003 clinical status , 2003, Current opinion in urology.

[153]  H. Ford,et al.  The influence of extent and local management on the outcome of radiotherapy for brain metastases. , 1990, International journal of radiation oncology, biology, physics.

[154]  D. Johnston,et al.  Analysis of clinicopathologic factors predicting outcome after radical prostatectomy , 2001, Cancer.

[155]  J. Gschwend,et al.  [Value of metastases surgery in metastatic renal cell carcinoma]. , 2002, Der Urologe. Ausg. A.

[156]  R. Figlin,et al.  SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[158]  R. Motzer,et al.  Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  N. Hensel,et al.  Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  M. Blute,et al.  Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. , 2000, The Journal of urology.

[161]  D. Johnston,et al.  Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. , 2002, The Journal of urology.

[162]  M. Burt,et al.  Resection of metastatic renal cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  R. Figlin,et al.  Renal cell carcinoma with retroperitoneal lymph nodes , 2003, Cancer.

[164]  M. Milowsky,et al.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.

[165]  J. Cheville,et al.  Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review , 2003, BJU international.

[166]  R. Figlin,et al.  Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. , 2004, International journal of radiation oncology, biology, physics.

[167]  J. Lovato,et al.  Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. , 2004, Urology.

[168]  R. Motzer,et al.  Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[169]  H. Bismuth,et al.  Hepatic Resection for Metastatic Renal Tumors: Is It Worthwhile? , 2003, Annals of Surgical Oncology.

[170]  S. Jacobs,et al.  Late development of renal carcinoma in allograft kidney. , 1992, The Journal of urology.

[171]  A. Bosi,et al.  Allogeneic stem cell transplantation. , 2005, Transplantation proceedings.

[172]  M. Gordon.  Novel Antiangiogenic Therapies for Renal Cell Cancer , 2004, Clinical Cancer Research.

[173]  T. Igarashi,et al.  The Identification of Renal Cell Carcinoma as a Target for Allogeneic Based Cancer Immunotherapy , 2002, Nephron Experimental Nephrology.

[174]  Daniel S. Miller,et al.  Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. , 2000, Archives of pathology & laboratory medicine.

[175]  S Nahum Goldberg,et al.  Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[176]  R. Childs,et al.  Allogeneic hematopoetic stem cell transplantation for cytokine refractory renal cell carcinoma. , 2003, Cancer treatment and research.

[177]  A. Ravaud,et al.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. , 1998, The New England journal of medicine.

[178]  W. Chow,et al.  Global increases in kidney cancer incidence, 1973–1992 , 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.